Northwest Bioth Cmn (NWBO): Price and Financial Metrics

Northwest Bioth Cmn (NWBO)

Today's Latest Price: $1.53 USD

0.13 (8.93%)

Updated Dec 2 3:59pm

Add NWBO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

NWBO Stock Summary

  • NWBO's price/sales ratio is 496.65; that's higher than the P/S ratio of 98.88% of US stocks.
  • Over the past twelve months, NWBO has reported earnings growth of 473.51%, putting it ahead of 97.02% of US stocks in our set.
  • The volatility of Northwest Biotherapeutics Inc's share price is greater than that of 98.48% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Northwest Biotherapeutics Inc are SPOK, KL, AWRE, LIZI, and FF.
  • Visit NWBO's SEC page to see the company's official filings. To visit the company's web site, go to

NWBO Stock Price Chart Interactive Chart >

Price chart for NWBO

NWBO Price/Volume Stats

Current price $1.53 52-week high $2.51
Prev. close $1.40 52-week low $0.14
Day low $1.36 Volume 4,142,229
Day high $1.54 Avg. volume 3,830,475
50-day MA $1.23 Dividend yield N/A
200-day MA $0.54 Market Cap 1.25B

Northwest Bioth Cmn (NWBO) Company Bio

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies. The company was founded in 1996 and is based in Bethesda, Maryland.

NWBO Latest News Stream

Event/Time News Detail
Loading, please wait...

NWBO Latest Social Stream

Loading social stream, please wait...

View Full NWBO Social Stream

Latest NWBO News From Around the Web

Below are the latest news stories about Northwest Biotherapeutics Inc that investors may wish to consider to help them evaluate NWBO as an investment opportunity.

Northwest Biotherapeutics secures loan financing of $5M

Northwest Biotherapeutics ([[NWBO]] +2.0%) has completed a non-dilutive debt financing for net proceeds of additional $5M, via a 21-month note for $5.5M at an 8% annualized interest rate, with no payments due for the first 7 months.The loan is expected to provide resources for certain readiness activities as the Company approaches the...

Seeking Alpha | August 21, 2020

Northwest Biotherapeutics secures capital raise of $8M

Northwest Biotherapeutics ([[NWBO]] -2.9%) has completed a financing of ~$8M, including ~$7M from offering at $0.32/share of new shares of ~21.8M shares with warrants averaging 21%, exercisable at $0.34 for ~5.3M shares, with an exercise period ranging from 18 to 30 months, and $1M notes, convertible at $0.345.The company also announced to...

Seeking Alpha | August 11, 2020

Northwest Biotherapeutics Announces Completion of Phase 3 Trial Sites' Databases

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the data collection from all of the clinical trial sites for the Company's Phase 3 trial of DCVax®-L for Glioblastoma brain cancer (the "Trial") has been completed and all of the sites have signed off on the locking of their data.

Yahoo | July 24, 2020

NW Bio Provides Update On Projected Timing For Data Lock For Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer

Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today reported progress toward data lock for the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer.

Yahoo | June 2, 2020

Did Northwest Biotherapeutics Just Check Off 1 Box Needed for Its Stock to Double?

Will a 14-year clinical trial evaluating an immunotherapy for the most lethal form of brain cancer have a positive outcome?

Yahoo | May 28, 2020

Read More 'NWBO' Stories Here

NWBO Price Returns

1-mo 28.58%
3-mo 178.43%
6-mo 322.65%
1-year 580.00%
3-year 436.84%
5-year -66.59%
YTD 611.96%
2019 4.57%
2018 -12.63%
2017 -32.43%
2016 -89.12%
2015 -40.19%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7126 seconds.